Cerebroprotein Hydrolysate is a sterile, pyrogen-free, low molecular weight preparation derived from porcine brain tissue through enzymatic hydrolysis. It contains biologically active peptides, free amino acids, and nucleotides. In the Indian market, it is primarily used as a neurotrophic and neuroprotective agent, believed to support neuronal survival, enhance synaptic plasticity, and promote functional recovery in various neurological conditions. It is administered via intramuscular injection or intravenous infusion.
Adult: 30mg to 60mg once daily, administered intramuscularly or by slow intravenous infusion in 100-250 mL of normal saline. The 60mg dose is common for moderate to severe conditions. A typical treatment course is 10-30 days, which may be repeated after an interval.
Note: For IM use: Administer by deep intramuscular injection. For IV use: Dilute the required dose in 100-250 mL of 0.9% Sodium Chloride Injection. Administer as a slow intravenous infusion over 60-90 minutes. Do not mix with other medications in the same infusion. A skin test is recommended before starting treatment: inject 0.1 mL of a 1:10 dilution intradermally; a wheal > 1.5 cm indicates positive reaction.
The exact mechanism is multifactorial and not fully elucidated. It is proposed to mimic the action of endogenous neurotrophic factors. The preparation contains a complex mixture of low molecular weight peptides (< 10 kDa) and amino acids that can cross the blood-brain barrier. It is believed to promote neuronal survival, stimulate neurite outgrowth, enhance synaptogenesis, and improve cerebral glucose utilization. It may also modulate neurotransmitter systems and possess antioxidant properties.
Pregnancy: Category N (Not classified). Animal reproduction studies have not been conducted. Due to its biological origin and unknown risk, use during pregnancy is not recommended unless the potential benefit justifies the potential risk to the fetus.
Driving: May cause dizziness and fatigue. Patients should be cautioned about operating machinery or driving until they know how the medication affects them.
| Anticoagulants (Warfarin, NOACs) | Theoretical risk of increased bleeding due to potential platelet inhibition; monitor coagulation parameters. | Moderate |
| Antiepileptic Drugs | Potential for lowered seizure threshold; may require adjustment of AED dose. | Moderate |
| Other Nootropic/Cerebral Activators (Piracetam, Citicoline) | Additive pharmacological effects; clinical significance unknown. | Mild |
| Antihypertensives | Potential additive hypotensive effect, especially with IV infusion; monitor BP. | Moderate |
Same composition (Cerebroprotein Hydrolysate (60mg)), different brands: